Bladder Cancer
A common malignancy of the urinary tract, heavily linked to smoking, typically presenting as painless blood in the urine, and treated with surgery and immunotherapy/chemotherapy.
Emergency Management: Clot retention causing acute urinary retention requires emergent bladder irrigation with a large-bore 3-way Foley catheter and continuous saline washout to clear the hematoma.
Bladder cancer is a malignant proliferation of the cells lining the urinary bladder. The vast majority of cases (over 90%) are urothelial carcinomas (formerly transitional cell carcinomas), originating from the urothelium. It is strongly associated with environmental exposures, most notably cigarette smoking, and primarily presents with painless hematuria.
Detailed Overview
The disease is broadly categorized into Non-Muscle Invasive Bladder Cancer (NMIBC, ~75% of new cases) and Muscle-Invasive Bladder Cancer (MIBC, ~25%). NMIBC has a high rate of recurrence but low mortality if appropriately managed with transurethral resection and intravesical therapy. Conversely, MIBC is an aggressive disease requiring radical surgical intervention (cystectomy), often coupled with neoadjuvant platinum-based chemotherapy, and carries a significant risk of distant metastasis to the lymph nodes, lungs, liver, and bone.
Epidemiology & Demographics
It is the 4th most common cancer in men in the US, but less common in women (approximate 3:1 male-to-female ratio). The median age at diagnosis is 73 years. The lifetime risk for men is roughly 1 in 27.
Etiological Mechanism
Carcinogenesis is primarily driven by urinary excretion of inhaled or ingested environmental carcinogens that have prolonged contact with the bladder urothelium.
Primary Causes
Tobacco smoke is the leading cause, accounting for about 50% of cases. Occupational exposure to aromatic amines (e.g., benzidine, beta-naphthylamine) used in the dye, rubber, and chemical industries is another major cause. Schistosoma haematobium infection is a common cause of squamous cell carcinoma of the bladder in endemic regions (e.g., Egypt).
Carcinogens in the urine induce DNA damage and genetic mutations in the urothelium. Urothelial carcinoma develops via two distinct molecular pathways. The papillary pathway typically involves activating mutations in FGFR3 and HRAS, leading to low-grade, non-invasive papillary tumors that frequently recur but rarely progress. The flat pathway involves early alterations in tumor suppressor genes, particularly TP53 and RB1, resulting in carcinoma in situ (CIS) and high-grade, aggressive tumors that rapidly invade the muscularis propria (detrusor muscle) and metastasize.
Diagnostic Criteria & Guidelines
Diagnosis is established visually and histologically via cystoscopy and transurethral resection of bladder tumor (TURBT). The tissue specimen must include underlying detrusor muscle to accurately stage the depth of invasion.
For NMIBC: Initial treatment is complete Transurethral Resection of Bladder Tumor (TURBT). A single post-operative instillation of intravesical chemotherapy (e.g., Mitomycin C or Gemcitabine) is given to reduce recurrence. For intermediate/high-risk NMIBC, induction with intravesical BCG (Bacillus Calmette-Guerin) for 6 weeks followed by maintenance therapy. For MIBC: Neoadjuvant cisplatin-based chemotherapy (e.g., MVAC or Gemcitabine/Cisplatin) followed by Radical Cystectomy with pelvic lymph node dissection and urinary diversion.
Second-Line & Adjunctive Therapy
For BCG-unresponsive NMIBC: Valrubicin, intravesical Pembrolizumab, Nadofaragene firadenovec, or early radical cystectomy. For Metastatic Bladder Cancer: First-line chemotherapy with Gemcitabine/Cisplatin. For platinum-ineligible or post-platinum patients, immune checkpoint inhibitors (Pembrolizumab, Avelumab, Nivolumab) or targeted agents (Erdafitinib for FGFR alterations, Enfortumab vedotin).
Surgical & Procedural Management
Transurethral Resection of Bladder Tumor (TURBT) is the gold standard for diagnosis and treatment of NMIBC. Radical Cystectomy involves removal of the bladder, prostate/seminal vesicles (males), or uterus/ovaries/anterior vagina (females). Urinary diversion is required (e.g., Ileal conduit/urostomy or orthotopic neobladder).
Patient Counseling & Advice
Stress that any episode of painless blood in the urine, even if it stops, requires full urologic evaluation. Warn patients with NMIBC about the necessity of rigorous, uncomfortable, but life-saving lifetime cystoscopic surveillance due to the high risk of recurrence.
Follow-Up & Monitoring Schedule
For NMIBC: Cystoscopy and urine cytology every 3-6 months for 2 years, then every 6-12 months for life. Upper tract imaging (CT Urogram) every 1-2 years.
Preventive Strategies
Primary prevention relies almost entirely on smoking cessation and workplace safety regulations regarding aromatic amines.
5-year survival for NMIBC is >90%. For organ-confined MIBC treated with cystectomy, 5-year survival is 50-70%. For metastatic disease, 5-year survival is roughly 5-15%, though novel immunotherapies are improving outcomes.